

10649194

=> d his

(FILE 'HOME' ENTERED AT 10:12:05 ON 07 OCT 2004)

FILE 'CAPLUS' ENTERED AT 10:12:31 ON 07 OCT 2004

L1 O S TRIAZOLO? (P) DIFLUORO (P) OXAZOL? (P) PYRIDIN?

FILE 'REGISTRY' ENTERED AT 10:14:18 ON 07 OCT 2004

E 668981-02-0/RN

L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:14:57 ON 07 OCT 2004

L3 4 S L2

=> d 1-4 bib abs hitstr

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:589283 CAPLUS

DN 141:140449

TI Preparation of novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine.

IN Kang, Ming; Li, Zheng Jane; Li, Zhengong Bryan; Tao, Yong

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 35 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004143119	A1	20040722	US 2003-649194	20030827
PRAI	US 2002-407158P	P	20020830		

AB Crystalline forms of 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (I) having specified x-ray crystallog., <sup>13</sup>C solid state NMR, and differential scanning calorimetry data were prepared. Thus, N- $\alpha$ -tosyl-(2,5-difluorobenzyl)isocyanide (preparation given), 3-isopropyl-1,2,4-triazolo[4,3-a]pyridine-6-carboxaldehyde (preparation given), and K<sub>2</sub>CO<sub>3</sub> were refluxed together for 22 h in MeCN to give 61% I. This was triturated in EtOAc/hexane followed by drying in vacuo at 40° for 48 h to give I form A.


IT 668981-02-0P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of novel crystalline forms of isopropylidifluorophenylloxazolyltriazolopyridine)

RN 668981-02-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:392324 CAPLUS

DN 140:406810

TI Preparation of alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolopyridines as MAP kinases, in particular p38 kinase inhibitors

IN Dombroski, Mark A.; Letavic, Michael A.; McClure, Kim F.

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 31 pp.



CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004092547	A1	20040513	US 2003-649227	20030827
PRAI US 2002-407088P	P	20020830		
OS MARPAT 140:406810				
GI				




AB Title compds. I [wherein R1 = F; n = 2; R2 = alkyl, optionally substituted by halo, OH, alkoxy, and alkoxy carbonyl; with certain compds. absent; their pharmaceutically acceptable salts] were prepared as potent inhibitors of MAP kinases, preferably p38 kinase. For example, II was prepared by Pd-cross coupling of 6-(4-bromooxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine (preparation given) with 2,5-difluoroboronic acid in the presence of TEA/EtOH/H<sub>2</sub>O. Selected I had an IC<sub>50</sub> < 10 μM in the TNF-α and MAPKAP in vitro assays, and an EC<sub>50</sub> < 50 mg/kg in the in vivo TNFα assay. I are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

IT **668981-02-0P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine  
 RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (p38 kinase inhibitor; preparation of alkyldifluorophenylloxazolyltriazolopyridines as MAP kinases, in particular p38 kinase inhibitors)

RN 668981-02-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2004:203834 CAPLUS  
 DN 140:235722  
 TI Preparation of 6-[4-(di- or trifluorophenyl)oxazol-5-yl][1,2,4]triazolo[4,3-a]pyridine as inhibitors of mitogen-activated protein (MAP) kinases  
 IN Dombroski, Mark Anthony; Letavic, Michael Anthony; McClure, Kim Francis  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004020440	A1	20040311	WO 2003-IB3847	20030819
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004053958	A1	20040318	US 2003-649236	20030827
PRAI US 2002-407177P	P	20020830		
OS MARPAT 140:235722				
GI				



AB The present invention relates to novel triazolo-pyridines of the formula (I) (wherein R1 is fluoro; m = 2,3; R2 is C3-6 cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-4 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; or R2 is C1-6 alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-6 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; with the proviso that said compound of this formula cannot be 6-[4-(2,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine or 6-[4-(3,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine) or pharmaceutically acceptable salt thereof; to intermediates for their preparation, and to pharmaceutical compns. containing them and to their medicinal use. The compds. I are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, a mixture of [ $\alpha$ -(p-toluenesulfonyl)-2,6-difluorobenzyl]isonitrile (1.79 g, 5.84 mmol), 3-isopropyl-[1,2,4]triazolo[4,3-a]-6-pyridinecarboxaldehyde (1.10 g, 5.84 mmol), potassium carbonate (1.05 g, 7.59 mmol) and acetonitrile (17.5 mL) was refluxed for 22 h to give, after workup and silica gel chromatog., 6-[4-(2,6-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine as a yellow solid. A tablet formulation containing 6-[4-(2,5-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine was prepared, which can be administered to a human from one to four times a day for inhibiting cartilage damage or treating osteoarthritis.


IT

**668981-02-0P**

RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(X-ray crystallog. data and polymorphism; preparation of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668981-02-0 CAPLUS  
 CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2004:203832 CAPLUS  
 DN 140:235721  
 TI Novel processes and intermediates for preparing [1,2,4]triazolo[4,3-a]pyridines  
 IN Buzon, Richard Allen Sr.; Castaldi, Michael James; Li, Zhengong Bryan;  
 Ripin, David Harold Brown; Tao, Yong  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 70 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004020438	A2	20040311	WO 2003-IB3669	20030818
	WO 2004020438	A3	20040722		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004053959	A1	20040318	US 2003-649247	20030827
PRAI	US 2002-407085P	P	20020830		
OS	CASREACT 140:235721; MARPAT 140:235721				
GI					



AB The present invention relates and intermediates to a novel process for preparing triazolo-pyridines of the formula (I) [R1 = H, cyano, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl or NH2; R3 = halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, perhalo-C1-6 alkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl, C3-10 cycloalkyl, HO, C1-6 alkoxy, perhalo-C1-10 alkoxy, PhO, C1-10 heteroaryloxy, C1-10 heterocyclxy-C3-10 cycloalkyloxy, C1-6 alkylthio, C1-16 alkylsulfonyl, C1-6 alkylsulfamoyl, amino, mono - or di(C1-6 alkyl)amino, C1-6 sulfonylamino, C1-6 alkyl-carbonylamino, etc.; or two adjacent R2 taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; m = an integer from 0-5; R4 = H, F, Cl, R5-B-(CH2)n-; n = n integer from 0-6; B = a bond, (CHR6), O, S, SO2, CO, O-CO, CO-O, CO-NR6, R6N, R6NSO2, R6NCO, SO2NR6, R6NCONR7, O-CONR6 or R6NCO-O; R5 = H, CF3, cyano, each (un)substituted Ph, C1-10 heterocyclyl, C1-10 heteroaryl, or C3-10 cycloalkyl, etc.; R6 = H, C1-6 alkylsulfonyl, C1-6 alkyl] or acceptable salts thereof, e.g., comprising reacting 6-(oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridines (II) (L = a leaving group and R1 and R4 are as defined above) with phenylboronic acids (III) and a transition metal catalyst. The compds. I prepared by the methods of the present invention are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, 6-(4-bromooxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine (33.0 g, 0.107 mol), 2,5-difluorophenylboronic acid (25.34 g, 0.1605 mol), Pd(PPh3)4 (12.36 g, 0.0107 mol), Et3N (22.37 mL, 0.1605 mol), 2B ethanol (495 mL), and water (33 mL), were added to a 2 L 4 neck round bottom flask (equipped with mech. stirring, nitrogen, heating mantle, temperature controller, and a condenser), stirred while heating to 65 to 70°, and kept stirring overnight at .apprx.70°. Two addnl. difluorophenylboronic acid (8.5 g, 0.054 mol) and Et3N (7.53 mL, 0.054 mol), were added and each time the reaction was allowed to proceed overnight at 70°. Toluene (30 mL) was added and the reaction was allowed to go overnight once again at 70°, treated with H2O (495 mL), and pot-granulated for 4 h at 20 to 25°. The solids were collected by vacuum filtration, washed with 2B ethanol/H2O (50:50) (25 mL of each), and dried in a vacuum oven at 45° for 4 h under full vacuum to afford 14.4 g 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (40.6% yield, 93.4% purity by HPLC).

IT **668981-02-0P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine  
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine derivative or cyclocondensation of  $\alpha$ -tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-02-0 CAPLUS  
 CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

